## James W Rocco

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/149210/publications.pdf

Version: 2024-02-01

23 papers 2,488 citations

16 h-index 713466 21 g-index

23 all docs

23 docs citations

times ranked

23

5532 citing authors

#	Article	IF	CITATIONS
1	Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer. Cell, 2017, 171, 1611-1624.e24.	28.9	1,656
2	Intra-tumor Genetic Heterogeneity and Mortality in Head and Neck Cancer: Analysis of Data from The Cancer Genome Atlas. PLoS Medicine, 2015, 12, e1001786.	8.4	244
3	Appraisal of the AJCC 8th edition pathologic staging modifications for HPVâ^'positive oropharyngeal cancer, a study of the National Cancer Data Base. Oral Oncology, 2017, 73, 152-159.	1.5	70
4	The challenges of tumor genetic diversity. Cancer, 2017, 123, 917-927.	4.1	67
5	Predictors of Complications in Patients Receiving Head and Neck Free Flap Reconstructive Procedures. Otolaryngology - Head and Neck Surgery, 2018, 158, 839-847.	1.9	61
6	Intraâ€ŧumor heterogeneity in head and neck cancer and its clinical implications. World Journal of Otorhinolaryngology - Head and Neck Surgery, 2016, 2, 60-67.	1.6	48
7	Molecular Aspects of Head and Neck Cancer Therapy. Hematology/Oncology Clinics of North America, 2015, 29, 971-992.	2.2	45
8	Risk Factors Associated With Postoperative Delirium in Patients Undergoing Head and Neck Free Flap Reconstruction. JAMA Otolaryngology - Head and Neck Surgery, 2019, 145, 216.	2.2	39
9	Margin Analysis in Head and Neck Cancer: State of the Art and Future Directions. Annals of Surgical Oncology, 2019, 26, 4070-4080.	1.5	37
10	Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2022, 28, 2329-2338.	7.0	31
11	Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study. Cancers, 2021, 13, 1180.	3.7	29
12	Respiratory and pulmonary complications in head and neck cancer patients: Evidenceâ€based review for the COVIDâ€19 era. Head and Neck, 2020, 42, 1218-1226.	2.0	26
13	National treatment trends in human papillomavirus–positive oropharyngeal squamous cell carcinoma. Cancer, 2020, 126, 1295-1305.	4.1	25
14	Quality Indicators: Measurement and Predictors in Head and Neck Cancer Free Flap Patients. Otolaryngology - Head and Neck Surgery, 2018, 158, 265-272.	1.9	24
15	Elective neck dissection for salvage laryngectomy: A systematic review and meta-analysis. Oral Oncology, 2019, 96, 97-104.	1.5	23
16	The future of circulating tumor DNA as a biomarker in HPV related oropharyngeal squamous cell carcinoma. Oral Oncology, 2022, 126, 105776.	1.5	22
17	Supine positioning for the subscapular system of flaps: A pictorial essay. Head and Neck, 2018, 40, 1068-1072.	2.0	18
18	Intratumor heterogeneity could inform the use and type of postoperative adjuvant therapy in patients with head and neck squamous cell carcinoma. Cancer, 2020, 126, 1895-1904.	4.1	11

#	Article	IF	CITATIONS
19	A combination of intra-tumor genetic heterogeneity, estrogen receptor alpha and human papillomavirus status predicts outcomes in head and neck squamous cell carcinoma following chemoradiotherapy. Oral Oncology, 2021, 120, 105421.	1.5	5
20	Predictors of Postoperative Radiation Following Laser Resection in Early-Stage Glottic Cancer. Otolaryngology - Head and Neck Surgery, 2020, 163, 1218-1225.	1.9	3
21	Outcomes with culture-directed antibiotics following microvascular free tissue reconstruction for osteonecrosis of the jaw. Oral Oncology, 2022, 130, 105878.	1.5	3
22	Predictors of survival following carotid blowout syndrome. Oral Oncology, 2022, 125, 105723.	1.5	1
23	ERα: A biomarker and treatment target for oropharyngeal cancer?. Oral Oncology, 2022, 124, 105637.	1.5	0